Quick verdict: AEHR vs LAES in 2026

In this comprehensive AEHR vs LAES stock comparison for 2026, SEALSQ Corp (LAES) emerges as the clear leader for growth and value investors, demonstrating superior revenue growth, more favorable valuation multiples, and unanimous analyst endorsement with significant upside potential. While Aehr Test Systems (AEHR) currently reports higher absolute revenue and significantly better (less negative) profitability margins, LAES shows stronger momentum and analyst confidence. Ultimately, LAES is the analyst favorite with the most projected upside, whereas AEHR currently exhibits more stable (though still negative) operational efficiency. Not investment advice.

AEHR vs LAES: key metrics side by side

Full side-by-side comparison of AEHR and LAES across valuation, profitability, growth and analyst sentiment. Data updated 2026-05-12.

AEHR vs LAES valuation comparison

When assessing the AEHR vs LAES valuation, SEALSQ Corp (LAES) appears to be considerably more attractive on several key metrics despite both companies operating at a loss. LAES currently trades at a P/E ratio of -12.08x, which, while negative, is significantly less negative than AEHR’s P/E of -281.14x. This suggests that the market assigns a much lower discount to LAES’s future earnings potential or perceives its path to profitability as less distant or less uncertain. Furthermore, LAES’s P/B ratio stands at 0.9x, indicating it trades below its book value, a classic sign of potential undervaluation, especially for a growth-oriented company. In contrast, AEHR’s P/B ratio is a substantial 23.12x, suggesting a high premium relative to its assets, which could imply market confidence in future growth or a rich valuation.

Considering the discounted cash flow (DCF) analysis, both companies show negative DCF values, indicating they are significantly overvalued based on current cash flow projections or that their future cash flows are deeply uncertain. AEHR has a DCF of $-1.5, representing a -101.4% downside, while LAES shows a DCF of $-0.68, with a -122.2% downside. Although both are deeply in negative territory, AEHR’s slightly less negative DCF upside (or less severe theoretical downside) is a marginal win. However, the P/E and P/B ratios collectively position LAES as the cheaper stock from a traditional valuation perspective, especially with its P/B trading below one, which is rare in the technology sector.

AEHR vs LAES growth comparison

In terms of growth, the AEHR vs LAES comparison paints a starkly different picture. SEALSQ Corp (LAES) demonstrates significantly stronger revenue momentum, reporting a impressive year-over-year revenue growth of 46.4%. This robust expansion suggests increasing market penetration and demand for its products or services, positioning LAES as a compelling option for growth-focused investors. Conversely, Aehr Test Systems (AEHR) faced a challenging period, experiencing a revenue decline of -10.9% year-over-year. This contraction indicates headwinds in its operations or market, which could be a concern for investors looking for top-line expansion.

While LAES is outpacing AEHR in revenue growth, it’s also important to consider the profitability margins as growth without a path to profitability is unsustainable. LAES’s gross margin of 47.28% is higher than AEHR’s 30.72%, indicating better efficiency at the cost of goods sold level. However, LAES’s significantly negative net margin (-187.34%) and EBITDA margin (-185.15%) suggest that its strong revenue growth is currently being offset by very high operating expenses. AEHR, while having negative revenue growth, exhibits substantially less negative net (-25.23%) and EBITDA (-29.97%) margins, indicating a more controlled cost structure despite declining sales. Investors must weigh LAES’s high growth potential against its current substantial unprofitability, versus AEHR’s revenue challenges but relatively better margin control.

AEHR vs LAES profitability

Evaluating the AEHR vs LAES profitability, Aehr Test Systems (AEHR) appears to be in a stronger position, despite both companies currently operating at a loss. AEHR reports a net margin of -25.23%, which, while negative, is considerably better than SEALSQ Corp’s (LAES) staggering net margin of -187.34%. This indicates that AEHR is far more efficient at controlling its costs relative to its revenue, translating more of its sales to (less negative) bottom-line performance. Similarly, AEHR’s EBITDA margin of -29.97% is significantly superior to LAES’s -185.15%, highlighting AEHR’s better operational efficiency before accounting for depreciation, amortization, interest, and taxes.

When it comes to return on equity (ROE), both companies report N/A%, suggesting either negative shareholder equity or complexities in calculation due to their developmental stages. However, in terms of free cash flow (FCF) yield, AEHR again demonstrates a more favorable (less negative) profile at -0.35% compared to LAES’s -9.17%. A less negative FCF yield for AEHR implies it is burning less cash relative to its market capitalization, which is a critical factor for early-stage or unprofitable companies. While neither company is currently generating positive free cash flow, AEHR’s ability to maintain a less severe cash burn rate suggests better financial management or a business model closer to sustainability.

Analyst ratings: AEHR vs LAES

In the realm of analyst sentiment, there’s a clear preference when comparing AEHR vs LAES. SEALSQ Corp (LAES) is a unanimous favorite among the analysts covering it, with 100.0% of the 2 analysts issuing a “Buy” rating. This strong conviction is further reinforced by a highly optimistic average price target of $7.5, which represents a substantial +145.1% upside from its current price of $3.06. Such robust support from the analyst community signals significant confidence in LAES’s future prospects and potential for considerable stock appreciation, making it a standout for investors valuing expert opinions and growth potential.

Conversely, Aehr Test Systems (AEHR) receives a more cautious assessment from analysts. Out of the 3 analysts covering AEHR, only 33.3% recommend a “Buy,” with the consensus leaning towards “Hold.” The average price target for AEHR stands at $62, which implies a significant -40.7% downside from its current price of $104.56. This indicates that analysts believe AEHR’s current valuation might be stretched or that its near-term growth catalysts are lacking. For investors considering these stocks, the difference in analyst conviction and projected price target upside between AEHR and LAES is a critical factor to ponder in their investment decision.

Should I buy AEHR or LAES stock in 2026?

For growth investors looking to capitalize on strong top-line expansion, LAES appears to be the more compelling choice in this AEHR vs LAES stock comparison for 2026. Its impressive 46.4% year-over-year revenue growth far outpaces AEHR’s -10.9% decline, indicating a company with significant market momentum and potentially expanding operations. While LAES is currently deeply unprofitable, its superior growth rate and higher gross margins suggest a business that is scaling rapidly, and investors might be betting on future profitability once scale is achieved.

When considering AEHR vs LAES fundamentals and valuation, LAES presents a more attractive profile for value-conscious investors willing to tolerate higher risk. Its P/E ratio of -12.08x, though negative, is considerably less extreme than AEHR’s -281.14x. More importantly, LAES trades at a P/B ratio of 0.9x, indicating it’s valued below its book value, suggesting potential undervaluation. In contrast, AEHR’s P/B of 23.12x reflects a much higher premium. While both companies have negative DCF calculations, pointing to deep uncertainty or overvaluation, LAES’s conventional valuation metrics present a comparatively more favorable entry point.

For income-seeking investors, neither AEHR nor LAES is suitable, as both companies currently pay no dividends, with a 0% dividend yield for each. Their focus remains on reinvesting in growth and operations rather than returning capital to shareholders. Therefore, if the question is “should i buy aehr or laes stock 2026” based on income, the answer is neither. Potential investors in either stock should be primarily focused on capital appreciation driven by future business success and market sentiment. This is not investment advice; always conduct your own thorough research.

More AEHR and LAES comparisons

AEHR full stock analysis · LAES full stock analysis · All stock comparisons

FAQ: AEHR vs LAES